162 related articles for article (PubMed ID: 36270630)
1. Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists
Orsi DL; Pook E; Bräuer N; Friberg A; Lienau P; Lemke CT; Stellfeld T; Brüggemeier U; Pütter V; Meyer H; Baco M; Tang S; Cherniack AD; Westlake L; Bender SA; Kocak M; Strathdee CA; Meyerson M; Eis K; Goldstein JT
J Med Chem; 2022 Nov; 65(21):14843-14863. PubMed ID: 36270630
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Orsi DL; Ferrara SJ; Siegel S; Friberg A; Bouché L; Pook E; Lienau P; Bluck JP; Lemke CT; Akcay G; Stellfeld T; Meyer H; Pütter V; Holton SJ; Korr D; Jerchel-Furau I; Pantelidou C; Strathdee CA; Meyerson M; Eis K; Goldstein JT
Bioorg Med Chem; 2023 Jan; 78():117130. PubMed ID: 36542958
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists.
Irwin S; Karr C; Furman C; Tsai J; Gee P; Banka D; Wibowo AS; Dementiev AA; O'Shea M; Yang J; Lowe J; Mitchell L; Ruppel S; Fekkes P; Zhu P; Korpal M; Larsen NA
J Biol Chem; 2022 Nov; 298(11):102539. PubMed ID: 36179791
[TBL] [Abstract][Full Text] [Related]
4. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
Mansure JJ; Nassim R; Kassouf W
Cancer Biol Ther; 2009 Apr; 8(7):6-15. PubMed ID: 19417560
[TBL] [Abstract][Full Text] [Related]
6. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
7. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
Miyamae Y
Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
[TBL] [Abstract][Full Text] [Related]
8. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
9. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs.
Puhl AC; Milton FA; Cvoro A; Sieglaff DH; Campos JC; Bernardes A; Filgueira CS; Lindemann JL; Deng T; Neves FA; Polikarpov I; Webb P
Nucl Recept Signal; 2015; 13():e004. PubMed ID: 26445566
[TBL] [Abstract][Full Text] [Related]
11. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells.
Han EJ; Im CN; Park SH; Moon EY; Hong SH
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e239-48. PubMed ID: 23332223
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
[TBL] [Abstract][Full Text] [Related]
15. Identification of a New Type of Covalent PPARγ Agonist using a Ligand-Linking Strategy.
Ohtera A; Miyamae Y; Yoshida K; Maejima K; Akita T; Kakizuka A; Irie K; Masuda S; Kambe T; Nagao M
ACS Chem Biol; 2015 Dec; 10(12):2794-804. PubMed ID: 26414848
[TBL] [Abstract][Full Text] [Related]
16. The Peroxisome Proliferator-Activated Receptor (PPAR)-
Schubert M; Becher S; Wallert M; Maeß MB; Abhari M; Rennert K; Mosig AS; Große S; Heller R; Grün M; Lorkowski S
Mol Pharmacol; 2020 Mar; 97(3):212-225. PubMed ID: 31871304
[TBL] [Abstract][Full Text] [Related]
17. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
18. Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.
Ren L; Konger RL
Mol Carcinog; 2019 Sep; 58(9):1589-1601. PubMed ID: 31111568
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
